Key points are not available for this paper at this time.
About one third of the world population has latent M. tuberculosis infection. This review explains the approach to patients with latent infection, including an update on the risks and benefits of treatment and assessment of the likelihood of progression to active disease.
Getahun et al. (Thu,) studied this question.